<DOC>
	<DOCNO>NCT00502164</DOCNO>
	<brief_summary>A study ass safety tolerability AZD2171 multiple dose patient advanced prostate cancer .</brief_summary>
	<brief_title>Study Assess Safety Tolerability AZD2171 After Multiple Doses Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Men , 18yrs old Histological cytological confirmation prostate adenocarcinoma ( symptomatic asymptomatic ) Prior hormonal therapy , and/or 1 prior chemotherapy regimen ( include estramustine and/or corticosteroid ) treatment prostate adenocarcinoma Prior radiotherapy bone metastasis within 4 week prior screen unresolved chronic toxicity great CTCAE grade 2 previous anticancer therapy Brain metastases spinal cord compression , unless treat least 4 week entry , stable steroid treatment 1 week .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Advanced Prostate Cancer</keyword>
</DOC>